You are subscribed to the FormularyWatch.

Formulary

eNewsletter Subscribe

March 16, 2015

Web Version  | Share with a colleague

Facebook Like Twitter Tweet

Today's Headlines

FDA opens up generic competition

FDA released new draft guidance designed to make it easier for generic manufacturers to introduce competition to 38 existing drug products, according to the agency's Federal Register notice. » Details

Anticholinergic drugs linked to higher risk for pneumonia in elderly

Taking commonly used medications with anticholinergic effects is associated with a significantly higher risk for developing pneumonia, according to a study published recently in the Journal of the American Geriatrics Society. » Read more

Continuing Education

2015 Updates on the national guidelines for diabetes management and related disorders

Last month and this month pharmacists will be able to learn about the latest developments in diabetes treatment and management. Pharmacists can earn up to 4 hours of CPE credit with two monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics. The goal of this month’s activity is to discuss the recent updates of national U.S. guidelines for diabetes management, including hypertension and cholesterol management in patients with diabetes, in order to empower pharmacists in clinical decision-making.

Read/print the article: Click here

Take the test: Click here to log in with the Session Code 15DT16-TAJ88.


Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

Takeda announces post hoc analysis of data from EXAMINE cardiovascular safety outcomes trial

In patients with type 2 diabetes and recent acute coronary syndrome, dipeptidyl peptidase 4 (DPP-4) inhibitor alogliptin compared to placebo did not increase the risk of heart failure outcomes, according to data published in The Lancet. » Read more

POLL:

A new class of biologics in the PCSK9 Inhibitors likely will be approved for treating high cholesterol. How are you preparing?

 

RELATED ARTICLES

Biosimilar drugs could save US billions

Sepsis patients return to hospital for preventable reasons; better post care needed

RESOURCES

Latest Clinical News

Powered by Modern Medicine Advanstar Medical Communications Group